haloperidol has been researched along with Chronic Disease in 279 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The plasma levels of ADA in patients with chronic schizophrenia who received clozapine were significantly higher than patients who received haloperidol." | 9.15 | Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. ( Akhondzadeh, S; Boroumand, MA; Ghaleiha, A; Honarbakhsh, N; Jafarinia, M; Raznahan, M; Rezaei, F; Tabrizi, M, 2011) |
| "To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment." | 9.13 | Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. ( Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL, 2008) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 9.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N=63) or a fixed dose of 8 mg/day of ondansetron (N=58) for 12 weeks." | 9.12 | Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. ( Kang, WH; Li, Q; Ma, AQ; Wang, XY; Yao, SM; Zhang, ZJ, 2006) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 9.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "44 patients with chronic DSM-IV schizophrenia were treated with clozapine or haloperidol decanoate in an open prospective 6-month trial." | 9.10 | The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. ( Mester, R; Shabash, E; Sheitman, B; Spivak, B; Weizman, A, 2003) |
| " typical (haloperidol) antipsychotic medication on facial emotion perception in schizophrenia (n=28) and healthy control (n=28) groups." | 9.10 | Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. ( Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM, 2003) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 9.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "The association of clinical characteristics with a sustained response was investigated in 37 partially treatment-refractory outpatients with a DSM-III-R diagnosis of chronic schizophrenia who had been assigned to clozapine treatment in a double-blind, haloperidol-controlled, long-term (29-week) study of clozapine." | 9.10 | Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. ( Kane, JM; Marder, SR; McMeniman, M; Schooler, NR; Umbricht, DS; Wirshing, DA; Wirshing, WC, 2002) |
| "The purpose of the study was to evaluate the effect of the classic antipsychotic haloperidol plus extract of ginkgo biloba (EGb) on treatment-resistant chronic schizophrenia and on blood superoxide dismutase (SOD) levels." | 9.09 | The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. ( Su, JM; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 9.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| "In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks." | 9.08 | Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. ( Peuskens, J, 1995) |
| "This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia." | 9.08 | Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 9.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol." | 9.08 | A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. ( Kim, YK; Lee, MS; Lee, SK; Suh, KY, 1998) |
| "Outpatients with schizophrenia who had histories of partial response to conventional neuroleptics and who had not responded to a prospective 6-week trial of fluphenazine participated in a 10-week, double-blind, parallel-groups comparison of clozapine and haloperidol." | 9.07 | Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. ( Breier, A; Buchanan, RW; Carpenter, WT; Davis, OR; Irish, D; Kirkpatrick, B; Summerfelt, A, 1994) |
| "A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia." | 9.07 | Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992) |
| "Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0." | 9.07 | Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991) |
| " However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution." | 9.06 | [Clinical experience with bromperidol in chronic psychoses]. ( Bellomo, LE; Forconesi, N; Rosset, N; Tellarini, L, 1988) |
| "Since an antipsychotic drug haloperidol has been clinically reported to induce QT interval prolongation and torsade de pointes, in this study its risk stratification for the onset of torsade de pointes was performed by using the chronic atrioventricular block canine model with a Holter electrocardiogram." | 7.85 | Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "This study examined the time-course of treatment response to haloperidol in chronic schizophrenia." | 7.68 | Early response to haloperidol treatment in chronic schizophrenia. ( Amin, F; Apter, SH; Harvey, PD; Hirschowitz, J; Kahn, RS; Stern, RG, 1993) |
| "The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed." | 7.67 | [Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988) |
| "Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor." | 6.70 | Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. ( Berk, M; Schutz, G, 2001) |
| "Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol." | 6.70 | Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| " The dosage calculation was made from the haloperidol doses previously received by the patients, adjusted in each particular case, with a mean of 73 mg per application (range, 50 to 200 mg)." | 6.66 | [Chronic treatment of schizophrenia with injectable bromperidol decanoate]. ( Suárez Richards, M, 1985) |
| "In a double blind chlorpromazine-controlled trial, high dosage haloperidol (100 mg daily) given for three months, appreciably improved the mental state of male chronic 'drug resistant' schizophrenic inpatients in the rehabilitation/long-stay unit of one psychiatric hospital." | 6.64 | High dosage haloperidol in chronic schizophrenia. ( MacDonald, IM; McCreadie, RG, 1977) |
| "Several cases of torsade de pointes have been reported in association with the use of oral haloperidol." | 6.40 | Torsade de pointes and low-dose oral haloperidol. ( Ditmanson, L; Jackson, T; Phibbs, B, 1997) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 5.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| " Chronic administration of RPD or HPD had no significant effect on (13)C-PBT indices in rats." | 5.38 | 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients. ( Chiba, S; Hattori, K; Higuchi, T; Hori, H; Iijima, Y; Kajiwara, M; Kawamoto, Y; Kinoshita, Y; Kunugi, H; Matsuo, J; Ota, M; Ozeki, Y; Sasayama, D; Tanaka, H; Terada, S; Teraishi, T; Yamamoto, N, 2012) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 5.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| "Chronic schizophrenic patients were maintained for six months on a dosage of haloperidol adjusted to give optimum clinical effect." | 5.26 | Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. ( Bishop, M; Coppen, A; Rao, VA, 1980) |
| "The plasma levels of ADA in patients with chronic schizophrenia who received clozapine were significantly higher than patients who received haloperidol." | 5.15 | Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. ( Akhondzadeh, S; Boroumand, MA; Ghaleiha, A; Honarbakhsh, N; Jafarinia, M; Raznahan, M; Rezaei, F; Tabrizi, M, 2011) |
| "Eighty hospitalized patients suffering from Schizophrenia or Schizoaffective disorder (male 54, female 26) were first treated with Haloperidol (N=60) or Fluphenazine (N=20), and then were switched to Risperidone." | 5.15 | First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. ( Popović, I; Popović, V; Ravanić, D; Stanojević, A; Stojanović, M; Vladejić, S, 2011) |
| "To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment." | 5.13 | Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. ( Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL, 2008) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 5.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N=63) or a fixed dose of 8 mg/day of ondansetron (N=58) for 12 weeks." | 5.12 | Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. ( Kang, WH; Li, Q; Ma, AQ; Wang, XY; Yao, SM; Zhang, ZJ, 2006) |
| "To study the effects of acetylcholinesterase inhibitors (AChEIs) in the management of cognitive impairments in patients with schizophrenia, we investigated the effects of 12 weeks of adjunctive therapy with donepezil on their cognitive impairments." | 5.12 | A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. ( Kim, YH; Lee, BJ; Lee, JG, 2007) |
| "44 patients with chronic DSM-IV schizophrenia were treated with clozapine or haloperidol decanoate in an open prospective 6-month trial." | 5.10 | The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. ( Mester, R; Shabash, E; Sheitman, B; Spivak, B; Weizman, A, 2003) |
| " typical (haloperidol) antipsychotic medication on facial emotion perception in schizophrenia (n=28) and healthy control (n=28) groups." | 5.10 | Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. ( Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM, 2003) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 5.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "The association of clinical characteristics with a sustained response was investigated in 37 partially treatment-refractory outpatients with a DSM-III-R diagnosis of chronic schizophrenia who had been assigned to clozapine treatment in a double-blind, haloperidol-controlled, long-term (29-week) study of clozapine." | 5.10 | Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. ( Kane, JM; Marder, SR; McMeniman, M; Schooler, NR; Umbricht, DS; Wirshing, DA; Wirshing, WC, 2002) |
| " In this long-term, open, randomised, multicentre trial, patients with chronic or subchronic schizophrenia received amisulpride (n =370) or haloperidol (n = 118) for 12 months." | 5.09 | Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. ( Colonna, L; Dondey-Nouvel, L; Rein, W; Saleem, P, 2000) |
| "The purpose of the study was to evaluate the effect of the classic antipsychotic haloperidol plus extract of ginkgo biloba (EGb) on treatment-resistant chronic schizophrenia and on blood superoxide dismutase (SOD) levels." | 5.09 | The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. ( Su, JM; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "During an 8-week period, 227 patients with DSM-III chronic schizophrenia received 4 mg/day of risperidone and 226 patients received 10 mg/day of haloperidol." | 5.09 | Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. ( Davidson, M; Hornik, T; Rabinowitz, J, 2001) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 5.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| "The hypothesis that differences in drug effects of risperidone and haloperidol on negative symptoms in schizophrenia are secondary to effects on positive, extrapyramidal, and depressive symptoms was investigated by means of an analysis of the data from the USA-Canada risperidone double-blind randomized clinical trial of 523 chronic schizophrenic patients." | 5.08 | A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. ( Borison, RL; Chouinard, G; Möller, HJ; Müller, H; Schooler, NR, 1995) |
| "In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks." | 5.08 | Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. ( Peuskens, J, 1995) |
| "This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia." | 5.08 | Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997) |
| "The current study uses utility analysis to assess economic and quality-of-life benefits of risperidone in patients with chronic schizophrenia." | 5.08 | Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. ( Albright, PS; Chouinard, G, 1997) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 5.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "We conducted a placebo-controlled, randomized, double-blind, 8-week trial of sertraline added to haloperidol treatment in patients with schizophrenia to evaluate changes in clinical measures and pharmacokinetic interactions with haloperidol." | 5.08 | A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. ( Kim, YK; Lee, MS; Lee, SK; Suh, KY, 1998) |
| "In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central 5-hydroxytryptamine2 and dopamine D2 antagonist), 2, 6, 10, 16 mg/day; haloperidol, 20 mg/day; or placebo, after a single-blind placebo washout period." | 5.07 | A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. ( Addington, D; Arnott, W; Beauclair, L; Bloom, D; Chouinard, G; Jones, B; Labelle, A; MacEwan, GW; Remington, G, 1993) |
| "Four patients with chronic schizophrenia were treated with a combination of fluvoxamine, haloperidol, and benztropine." | 5.07 | Coadministration of fluvoxamine increases serum concentrations of haloperidol. ( Abi-Dargham, A; Daniel, DG; Egan, M; Elkashef, A; Handel, S; Jaskiw, G; Liboff, S; Randolph, C; Shoaf, S; Williams, T, 1994) |
| "Outpatients with schizophrenia who had histories of partial response to conventional neuroleptics and who had not responded to a prospective 6-week trial of fluphenazine participated in a 10-week, double-blind, parallel-groups comparison of clozapine and haloperidol." | 5.07 | Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. ( Breier, A; Buchanan, RW; Carpenter, WT; Davis, OR; Irish, D; Kirkpatrick, B; Summerfelt, A, 1994) |
| "A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia." | 5.07 | Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992) |
| "Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0." | 5.07 | Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991) |
| " However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution." | 5.06 | [Clinical experience with bromperidol in chronic psychoses]. ( Bellomo, LE; Forconesi, N; Rosset, N; Tellarini, L, 1988) |
| "Thirty patients with chronic schizophrenia received oral haloperidol and haloperidol decanoate in a two-phase open study." | 5.06 | A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. ( Achim, A; Lizondo, E; Nayak, R; Schwartz, G; Suranyi-Cadotte, B; Thavundayil, JX; Vasavan Nair, NP, 1986) |
| "To determine the cost-effectiveness of PP3M compared with once-monthly paliperidone (PP1M), haloperidol long-acting therapy (HAL-LAT), risperidone microspheres (RIS-LAT), and oral olanzapine (oral-OLZ) for treating chronic schizophrenia in The Netherlands." | 3.85 | Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. ( Bereza, BG; Denee, TR; Dries, PJT; Einarson, TR; Tedouri, F; Van Impe, K, 2017) |
| "Since an antipsychotic drug haloperidol has been clinically reported to induce QT interval prolongation and torsade de pointes, in this study its risk stratification for the onset of torsade de pointes was performed by using the chronic atrioventricular block canine model with a Holter electrocardiogram." | 3.85 | Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "A haloperidol-treated patient with chronic schizophrenia had a near-arrhythmic circadian rest-activity cycle, whereas rhythms of 6-sulphatoxy-melatonin and core body temperature were of normal amplitude and phase-advanced." | 3.69 | A schizophrenic patient with an arrhythmic circadian rest-activity cycle. ( Cajochen, C; Nussbaum, P; Wirz-Justice, A, 1997) |
| "This study examined the time-course of treatment response to haloperidol in chronic schizophrenia." | 3.68 | Early response to haloperidol treatment in chronic schizophrenia. ( Amin, F; Apter, SH; Harvey, PD; Hirschowitz, J; Kahn, RS; Stern, RG, 1993) |
| "The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed." | 3.67 | [Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988) |
| "Thirty-nine patients with chronic schizophrenia for whom hospitalization was clinically indicated received haloperidol for 4 to 6 weeks in a standardized dose schedule." | 3.67 | Familial schizophrenia and treatment response. ( Breitner, JC; Davidson, M; Davis, KL; Keefe, RS; Losonczy, MF; Mohs, RC; Silverman, JM; Sorokin, JE, 1987) |
| "Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor." | 2.70 | Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. ( Berk, M; Schutz, G, 2001) |
| "Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol." | 2.70 | Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "Haloperidol decanoate is a long-acting depot antipsychotic agent used for the treatment of schizophrenic patients." | 2.68 | A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. ( Chang, WH; Jann, MW; Lin, HN; Piao-Chien, C; Wei, FC, 1996) |
| "Haloperidol dose was negatively associated with improvement in positive symptoms (r = -." | 2.68 | Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics. ( Pardo, M; Pollack, S; Weisbard, JJ, 1997) |
| " The plasma RHAL:HAL ratios on days 6 and 7 were higher than and positively correlated with those at Tmax after a single dose of HAL and were negatively correlated with the HAL:RHAL ratios at Tmax after a single dose of RHAL." | 2.66 | Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. ( Chang, WH; Chen, CT; Chen, TY; Hu, WH; Jann, MW; Lam, YW; Lin, SK; Yeh, EK, 1989) |
| " The dosage calculation was made from the haloperidol doses previously received by the patients, adjusted in each particular case, with a mean of 73 mg per application (range, 50 to 200 mg)." | 2.66 | [Chronic treatment of schizophrenia with injectable bromperidol decanoate]. ( Suárez Richards, M, 1985) |
| "Haloperidol appeared to produce lower levels of psychopathology than flupenthixol but similar levels of side effects." | 2.66 | Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol. ( Beninger, RJ; Delva, NJ; Ehmann, TS, 1987) |
| "Treatment with sulpiride was associated with a significant rise in plasma prolactin level, but paradoxically these patients had significantly reduced extrapyramidal symptoms." | 2.65 | A clinical and pharmacodynamic evaluation of sulpiride. ( Bailey, J; Bishop, M; Coppen, A; Rao, VA, 1981) |
| "In a double blind chlorpromazine-controlled trial, high dosage haloperidol (100 mg daily) given for three months, appreciably improved the mental state of male chronic 'drug resistant' schizophrenic inpatients in the rehabilitation/long-stay unit of one psychiatric hospital." | 2.64 | High dosage haloperidol in chronic schizophrenia. ( MacDonald, IM; McCreadie, RG, 1977) |
| "Haloperidol has proved to be remarkably safe in this high dose regimen." | 2.64 | Higher than usual dosage of haloperidol: a pilot study in 'back ward' schizophrenics. ( Declercq, H; Tanghe, A, 1976) |
| "The prognosis of CCI patients with coma or delirium has not yet been thoroughly studied, but preliminary studies suggest this population is at high risk for detrimental outcomes associated with acute brain dysfunction." | 2.48 | Brain dysfunction in patients with chronic critical illness. ( Girard, TD, 2012) |
| " Safety was monitored by open adverse event reporting, the Simpson-Angus Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement scale." | 2.41 | Safety profile of amisulpride in short- and long-term use. ( Coulouvrat, C; Dondey-Nouvel, L; Rein, W, 2000) |
| "Several cases of torsade de pointes have been reported in association with the use of oral haloperidol." | 2.40 | Torsade de pointes and low-dose oral haloperidol. ( Ditmanson, L; Jackson, T; Phibbs, B, 1997) |
| "Treatment with haloperidol is useful for 80% to 85% of patients but associated with troublesome side effects in one-half of those treated." | 2.36 | Tics in childhood. ( Golden, GS, 1983) |
| " In chronic unresponsive schizophrenic patients, poor drug bioavailability is not the major factor for the lack of response, and the possibility that these patients constitute a nosological subgroup is suggested." | 2.36 | Haloperidol plasma level monitoring in neuropsychiatric patients. ( Bianchetti, G; Dugas, M; Morselli, PL, 1982) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 1.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Treating schizophrenia is costly for health systems." | 1.43 | Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. ( Bereza, BG; Einarson, TR; Goswami, P; Maia-Lopes, S; Van Impe, K, 2016) |
| "Simvastatin could increase expression of exon-IIC transcripts in stressed mice." | 1.40 | Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastatin [correction of simvastain] in chronic mild stress in mice: a possible link with dopaminergic pathway. ( Goyal, RK; Jhala, MK; Joshi, CG; Patel, AK; Rana, DG, 2014) |
| " Chronic administration of RPD or HPD had no significant effect on (13)C-PBT indices in rats." | 1.38 | 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients. ( Chiba, S; Hattori, K; Higuchi, T; Hori, H; Iijima, Y; Kajiwara, M; Kawamoto, Y; Kinoshita, Y; Kunugi, H; Matsuo, J; Ota, M; Ozeki, Y; Sasayama, D; Tanaka, H; Terada, S; Teraishi, T; Yamamoto, N, 2012) |
| "In the present study we have investigated the effects of a chronic administration of olanzapine (Ola) on visual and spatial memory in normal and anhedonic rats." | 1.34 | Modification of spatial recognition memory and object discrimination after chronic administration of haloperidol, amitriptyline, sodium valproate or olanzapine in normal and anhedonic rats. ( Canonico, PL; Colella, L; Dellarole, A; Ghi, P; Orsetti, M, 2007) |
| " The main effect of the long-term administration of haloperidol seems to be an increase of cerebellar, basal ganglia and motor area metabolism." | 1.32 | Cerebral metabolic patterns in chronic and recent-onset schizophrenia. ( Benito, C; Desco, M; Gispert, JD; Molina, V; Palomo, T; Pascau, J; Reig, S; Santos, A; Sanz, J; Sarramea, F, 2003) |
| " A mean therapeutic dosage for Seroquel was 316." | 1.32 | [Influence of long-term quetiapine (Seroquel) and haloperidol therapy on cognitive deficit in patients with paranoid schizophrenia]. ( Kabanov, SO; Mosolov, SN, 2004) |
| " Moreover, chronic administration of haloperidol failed to decrease serum BDNF levels in adult rats." | 1.31 | Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. ( Asama, K; Muratake, T; Nawa, H; Someya, T; Takahashi, M; Toyooka, K; Watanabe, Y, 2002) |
| "In addition to the diagnosis of chronic pseudoakathisia, five patients (62." | 1.31 | Prevalence and characteristics of patients with pseudoakathisia. ( Christodoulou, GN; Havaki-Kontaxaki, BJ; Kontaxakis, VP, 2000) |
| "A careful history suggested that Tourette's syndrome might be responsible for the patients' symptoms." | 1.30 | Tourette's syndrome mimicking asthma. ( Hogan, MB; Wilson, NW, 1999) |
| "Haloperidol decanoate was initiated using the loading-dose regimen in 16 chronically ill patients." | 1.29 | A loading-dose strategy for converting from oral to depot haloperidol. ( Anderson, C; Ereshefsky, L; Saklad, SR; Seidel, D; Toney, G, 1993) |
| " Gross toxic side effects (seizures, catatonia, confusion) and Neuroleptic Induced Deficit Syndrome in conjunction with blood levels over 30 ng/ml were identified in 13 of our 43 patients." | 1.29 | Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. ( Clark, L; Dabiri, L; Darby, JK; Mosbacher, D; Pasta, DJ, 1995) |
| " The study indicates that haloperidol decanoate even in low dosage is effective maintenance therapy is preventing relapse." | 1.28 | Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. ( Youssef, HA, 1991) |
| " This means that it has a long half-life measurable in months rather than weeks." | 1.28 | Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. ( Cooper, TB; Levinson, DF; Lo, ES; Simpson, GM; Stephanos, MJ; Yadalam, KG, 1990) |
| "The authors review the literature on tactile hallucinations." | 1.28 | A case study: schizophrenia and tactile hallucinations, treated with electroconvulsive therapy. ( England, RD; Salama, AA, 1990) |
| "RBC choline concentration was significantly lower in patients medicated with neuroleptics and cogentin." | 1.28 | RBC and plasma choline in neuroleptic-treated schizophrenic patients. ( Hanin, I; Jeste, DV; Kopp, U; Lawson, WB; Wyatt, RJ, 1989) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 1.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| "A positive FH-NIDDM was significantly associated with the presence of TD and with higher drug-free FBS." | 1.28 | Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. ( Mukherjee, S; Roth, SD; Sandyk, R; Schnur, DB, 1989) |
| " The dosage schema can be adapted individually whenever necessary." | 1.27 | [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate]. ( Roncoroni, D, 1984) |
| "Treatment with haloperidol normalized the low ratio." | 1.27 | Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. ( Bigelow, LB; Karoum, F; Karson, CN; Lawson, WB; Wyatt, RJ, 1987) |
| "Haloperidol was given to 8 patients for 10 days (group A: 0." | 1.27 | Effects of neuroleptic treatments on peripheral opioid secretion. ( Bellodi, L; Brambilla, F; Brancato, V; Facchinetti, F; Genazzani, AR; Petraglia, F; Smeraldi, E, 1987) |
| "We report a patient in whom Tourette's syndrome (TS) and Type I schizophrenia coincided, and suggest, based on clinical features and pharmacological responses, that both conditions in this patient could have a common pathophysiological basis." | 1.27 | Gilles de la Tourette's syndrome associated with chronic schizophrenia. ( Bamford, CR; Sandyk, R, 1988) |
| " Serum haloperidol levels in these patients decreased to about 60% of the levels seen just prior to the usual morning dosing during the drug holiday." | 1.27 | Drug holidays and serum haloperidol levels in schizophrenic patients. ( Couch, L; Fody, EP; Harrison, RH; McMillan, DE; Newton, JE; Reese, WG, 1986) |
| "Eighteen chronic schizophrenic subjects treated with a uniform dosage (4-6 mg/day p." | 1.27 | Computed tomography and pattern reversal visual evoked potentials in chronic schizophrenic patients. ( Callieco, R; Cosi, V; Mariotti, G; Romani, A; Zerbi, F, 1986) |
| "Polydipsia and polyuria have a long association with schizophrenia." | 1.27 | Increased urine volume in chronic schizophrenic patients. ( Bigelow, LB; Karson, CN; Lawson, WB, 1985) |
| "Haloperidol was administered orally to 6 male schizophrenic patients and intravenously to 3." | 1.27 | Elimination half-life and bioavailability of haloperidol in schizophrenic patients. ( Hollister, LE; Magliozzi, JR, 1985) |
| "Chronic schizophrenic patients were maintained for six months on a dosage of haloperidol adjusted to give optimum clinical effect." | 1.26 | Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. ( Bishop, M; Coppen, A; Rao, VA, 1980) |
| "Haloperidol levels were measured by radioreceptor assay in 12 schizophrenic patients during gradual dosage reduction (at 10-day) intervals) from 60 to 0 mg/day." | 1.26 | Haloperidol blood levels during dosage reduction in chronic schizophrenic patients. ( Belmaker, RH; Ebstein, RP; Goldman, Z; Hermoni, M; Lerer, B; Zohar, J, 1981) |
| ") every 4 weeks with haloperidol decanoate using different dosage schedules which were calculated from the previously prescribed daily oral dose of haloperidol multiplied by a factor of 30, 20 or 10." | 1.26 | Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study. ( Berghmans, W; Deberdt, R; Driesens, F; Elens, P; Heykants, J; Reyntjens, A; van Wijngaarden, I; Woestenborghs, R, 1980) |
| " Data in adult patients illustrate on the one hand possible causes of variability in plasma levels of haloperidol and, on the other hand, the fact that poor bioavailability is not the cause of lack of response in 'resistant' schizophrenic patients." | 1.26 | Clinical significance of monitoring plasma levels of psychotropic drugs. ( Morselli, PL; Zarifian, E, 1979) |
| " A dosage schedule for in- and outpatients has been established, using imipramine (Tofranil) or chlorimipramine (Anafranil), and haloperidol (Haldol)." | 1.26 | The use of psychotropic drugs in the treatment of chronic, severe pains. ( Kocher, R, 1976) |
| "Haloperidol was given for 30 days, at a daily dose of 6 mg i." | 1.25 | Growth hormone secretion in chronic schizophrenia. ( Brambilla, F; Guastalla, A; Guerrini, A; Recchia, M; Riggi, F; Rovere, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 127 (45.52) | 18.7374 |
| 1990's | 82 (29.39) | 18.2507 |
| 2000's | 55 (19.71) | 29.6817 |
| 2010's | 15 (5.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Espinosa-Juárez, JV | 1 |
| Jaramillo-Morales, OA | 1 |
| López-Muñoz, FJ | 1 |
| Einarson, TR | 2 |
| Bereza, BG | 2 |
| Tedouri, F | 1 |
| Van Impe, K | 2 |
| Denee, TR | 1 |
| Dries, PJT | 1 |
| Kim, DD | 1 |
| Lang, DJ | 1 |
| Procyshyn, RM | 1 |
| Woodward, ML | 1 |
| Kaufman, K | 1 |
| White, RF | 1 |
| Honer, WG | 1 |
| Warburton, DER | 1 |
| Rana, DG | 1 |
| Patel, AK | 1 |
| Joshi, CG | 1 |
| Jhala, MK | 1 |
| Goyal, RK | 1 |
| Stepan, J | 1 |
| Hladky, F | 1 |
| Uribe, A | 1 |
| Holsboer, F | 1 |
| Schmidt, MV | 1 |
| Eder, M | 1 |
| Maia-Lopes, S | 1 |
| Goswami, P | 1 |
| Pinacho, R | 1 |
| Vila, E | 1 |
| Prades, R | 1 |
| Tarragó, T | 1 |
| Castro, E | 1 |
| Ferrer, I | 1 |
| Ramos, B | 1 |
| Izumi-Nakaseko, H | 1 |
| Nakamura, Y | 1 |
| Cao, X | 1 |
| Wada, T | 1 |
| Ando, K | 1 |
| Sugiyama, A | 1 |
| Kelley, ME | 2 |
| Haas, GL | 1 |
| van Kammen, DP | 5 |
| Stone, EA | 1 |
| Lin, Y | 2 |
| Quartermain, D | 1 |
| Zhang, XY | 4 |
| Zhou, DF | 4 |
| Qi, LY | 1 |
| Chen, S | 1 |
| Cao, LY | 3 |
| Chen, DC | 1 |
| Xiu, MH | 1 |
| Wang, F | 1 |
| Wu, GY | 3 |
| Lu, L | 1 |
| Kosten, TA | 1 |
| Kosten, TR | 1 |
| Danilov, DS | 1 |
| Bernstein, HG | 1 |
| Ernst, T | 1 |
| Lendeckel, U | 1 |
| Bukowska, A | 1 |
| Ansorge, S | 1 |
| Stauch, R | 1 |
| Have, ST | 1 |
| Steiner, J | 1 |
| Dobrowolny, H | 1 |
| Bogerts, B | 1 |
| Shibuya, M | 1 |
| Komi, E | 1 |
| Wang, R | 1 |
| Kato, T | 1 |
| Watanabe, Y | 2 |
| Sakai, M | 1 |
| Ozaki, M | 1 |
| Someya, T | 3 |
| Nawa, H | 3 |
| Ghaleiha, A | 1 |
| Honarbakhsh, N | 1 |
| Boroumand, MA | 1 |
| Jafarinia, M | 1 |
| Tabrizi, M | 1 |
| Rezaei, F | 1 |
| Raznahan, M | 1 |
| Akhondzadeh, S | 2 |
| Popović, I | 1 |
| Ravanić, D | 1 |
| Popović, V | 1 |
| Vladejić, S | 1 |
| Stanojević, A | 1 |
| Stojanović, M | 1 |
| Girard, TD | 1 |
| Teraishi, T | 1 |
| Ozeki, Y | 1 |
| Hori, H | 1 |
| Sasayama, D | 1 |
| Chiba, S | 1 |
| Yamamoto, N | 1 |
| Tanaka, H | 1 |
| Iijima, Y | 1 |
| Matsuo, J | 1 |
| Kawamoto, Y | 1 |
| Kinoshita, Y | 1 |
| Hattori, K | 1 |
| Ota, M | 1 |
| Kajiwara, M | 1 |
| Terada, S | 1 |
| Higuchi, T | 3 |
| Kunugi, H | 1 |
| Toyooka, K | 2 |
| Asama, K | 1 |
| Muratake, T | 1 |
| Takahashi, M | 1 |
| Genel, F | 1 |
| Erermis, S | 1 |
| Aksu, G | 1 |
| Ozturk, C | 1 |
| Kutukculer, N | 1 |
| Iritani, S | 1 |
| Makifuchi, T | 1 |
| Shirakawa, O | 1 |
| Kitamura, N | 1 |
| Maeda, K | 1 |
| Nakamura, R | 1 |
| Niizato, K | 1 |
| Watanabe, M | 1 |
| Kakita, A | 1 |
| Takahashi, H | 1 |
| Molina, V | 2 |
| Gispert, JD | 2 |
| Reig, S | 2 |
| Sanz, J | 2 |
| Pascau, J | 2 |
| Santos, A | 2 |
| Palomo, T | 2 |
| Desco, M | 2 |
| Osser, DN | 1 |
| Akhter, A | 1 |
| Sarramea, F | 1 |
| Benito, C | 1 |
| Wynchank, D | 1 |
| Berk, M | 2 |
| Spivak, B | 4 |
| Shabash, E | 1 |
| Sheitman, B | 2 |
| Weizman, A | 5 |
| Mester, R | 2 |
| EVRARD, E | 1 |
| MOLDERS, V | 1 |
| Nejatisafa, AA | 1 |
| Amini, H | 1 |
| Mohammadi, MR | 1 |
| Larijani, B | 1 |
| Kashani, L | 1 |
| Raisi, F | 1 |
| Kamalipour, A | 1 |
| Williams, LM | 1 |
| Loughland, CM | 1 |
| Green, MJ | 1 |
| Harris, AW | 1 |
| Gordon, E | 1 |
| Shim, JC | 2 |
| Kelly, DL | 3 |
| Kim, YH | 2 |
| Yoon, YR | 1 |
| Park, JH | 2 |
| Shin, JG | 1 |
| Conley, RR | 3 |
| Good, KP | 1 |
| Rabinowitz, J | 3 |
| Whitehorn, D | 1 |
| Harvey, PD | 3 |
| DeSmedt, G | 1 |
| Kopala, LC | 1 |
| Buckley, PF | 1 |
| Goldstein, JM | 1 |
| Emsley, RA | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Schmitt, A | 1 |
| Bertsch, T | 1 |
| Henning, U | 1 |
| Tost, H | 1 |
| Klimke, A | 1 |
| Henn, FA | 1 |
| Falkai, P | 1 |
| Jung, DU | 1 |
| Seo, YS | 1 |
| Jeong, CY | 1 |
| Perkins, DO | 1 |
| Johnson, JL | 1 |
| Hamer, RM | 1 |
| Zipursky, RB | 1 |
| Keefe, RS | 4 |
| Centorrhino, F | 1 |
| Green, AI | 1 |
| Glick, IB | 1 |
| Kahn, RS | 4 |
| Sharma, T | 1 |
| Tohen, M | 1 |
| McEvoy, JP | 3 |
| Weiden, PJ | 1 |
| Lieberman, JA | 2 |
| Orsetti, M | 1 |
| Colella, L | 1 |
| Dellarole, A | 1 |
| Canonico, PL | 1 |
| Ghi, P | 1 |
| Glick, ID | 1 |
| Shkedy, Z | 1 |
| Schreiner, A | 1 |
| Zhang, ZJ | 1 |
| Kang, WH | 1 |
| Li, Q | 1 |
| Wang, XY | 1 |
| Yao, SM | 1 |
| Ma, AQ | 1 |
| Lee, BJ | 1 |
| Lee, JG | 1 |
| Perez-Iglesias, R | 1 |
| Crespo-Facorro, B | 1 |
| Martinez-Garcia, O | 1 |
| Ramirez-Bonilla, ML | 1 |
| Alvarez-Jimenez, M | 1 |
| Pelayo-Teran, JM | 1 |
| Garcia-Unzueta, MT | 1 |
| Amado, JA | 1 |
| Vazquez-Barquero, JL | 1 |
| Lapolla, A | 1 |
| Luchins, DJ | 1 |
| Weinberger, DR | 4 |
| Kleinman, JE | 4 |
| Neckers, L | 1 |
| Rosenblatt, JE | 2 |
| Bigelow, LB | 7 |
| Wyatt, RJ | 9 |
| Ringwald, E | 1 |
| Lustig, A | 1 |
| Moscovici, M | 1 |
| Spiegel, R | 1 |
| Vamos, E | 1 |
| DeLisi, LE | 1 |
| Wise, CD | 1 |
| Bridge, TP | 1 |
| Wagner, RL | 2 |
| Morihisa, J | 1 |
| Karson, C | 1 |
| Potkin, SG | 1 |
| Baron, M | 2 |
| Gruen, R | 2 |
| Levitt, M | 2 |
| Kane, J | 2 |
| Roncoroni, D | 1 |
| Rivera-Calimlim, L | 1 |
| Hershey, L | 1 |
| Youssef, HA | 2 |
| Brambilla, F | 6 |
| Genazzani, AR | 2 |
| Facchinetti, F | 2 |
| Parrini, D | 1 |
| Petraglia, F | 2 |
| Sacchetti, E | 1 |
| Scarone, S | 2 |
| Gustalla, A | 1 |
| D'Antona, N | 1 |
| Golden, GS | 1 |
| Donoso, A | 1 |
| Vera, G | 1 |
| Arancibia, A | 1 |
| Díaz, E | 1 |
| Schilkrut, R | 1 |
| Miserda, R | 1 |
| Kohen, P | 1 |
| Pak, N | 1 |
| Pugnetti, L | 1 |
| Massironi, R | 1 |
| Penati, G | 1 |
| Nobile, P | 1 |
| McBurney, A | 1 |
| George, S | 1 |
| Bjørndal, N | 1 |
| Bjerre, M | 1 |
| Gerlach, J | 1 |
| Kristjansen, P | 1 |
| Magelund, G | 1 |
| Oestrich, IH | 1 |
| Waehrens, J | 1 |
| Nair, NP | 2 |
| Lal, S | 1 |
| Schwartz, G | 2 |
| Thavundayil, JX | 2 |
| Rao, VA | 2 |
| Bailey, J | 1 |
| Bishop, M | 2 |
| Coppen, A | 2 |
| Rimón, R | 1 |
| Terenius, L | 1 |
| Averbuch, I | 1 |
| Belmaker, RH | 3 |
| Morselli, PL | 4 |
| Bianchetti, G | 1 |
| Dugas, M | 1 |
| Glazer, WM | 1 |
| Sheard, MH | 1 |
| Wolf, ME | 1 |
| Bowie, L | 1 |
| Keener, S | 1 |
| Mosnaim, AD | 1 |
| Dincsoy, HP | 1 |
| Saelinger, DA | 1 |
| Karson, CN | 3 |
| Hollister, LE | 2 |
| Kim, DY | 1 |
| Reyntigens, AJ | 1 |
| Heykants, JJ | 1 |
| Woestenborghs, RJ | 1 |
| Gelders, YG | 2 |
| Aerts, TJ | 2 |
| Reyntijens, AJ | 1 |
| Ash, CW | 1 |
| Psaras, M | 1 |
| Zissis, NP | 1 |
| Mouzakis, D | 1 |
| Lyketsos, G | 1 |
| Goldman, Z | 1 |
| Ebstein, RP | 1 |
| Lerer, B | 3 |
| Zohar, J | 1 |
| Hermoni, M | 1 |
| Hoaki, Y | 1 |
| Nishikawa, T | 1 |
| Ida, Y | 1 |
| Kohno, Y | 1 |
| Tanaka, M | 1 |
| Slotnick, VB | 1 |
| Rubin, RT | 1 |
| Forsman, A | 2 |
| Heykants, J | 2 |
| Ohman, R | 1 |
| Tower, B | 1 |
| Michiels, M | 1 |
| Deberdt, R | 1 |
| Elens, P | 1 |
| Berghmans, W | 1 |
| Woestenborghs, R | 1 |
| Driesens, F | 1 |
| Reyntjens, A | 1 |
| van Wijngaarden, I | 1 |
| Bergman, A | 1 |
| O'Brien, J | 1 |
| Osgood, G | 1 |
| Cornblatt, B | 1 |
| Möller, HJ | 5 |
| Müller, H | 1 |
| Borison, RL | 1 |
| Schooler, NR | 2 |
| Chouinard, G | 3 |
| Peuskens, J | 3 |
| Lee, HS | 1 |
| Song, DH | 1 |
| Kim, JH | 1 |
| Lee, YM | 1 |
| Han, ES | 1 |
| Yoo, KJ | 1 |
| Jones, B | 2 |
| Remington, G | 1 |
| Bloom, D | 1 |
| Addington, D | 1 |
| MacEwan, GW | 1 |
| Labelle, A | 1 |
| Beauclair, L | 1 |
| Arnott, W | 1 |
| Min, SK | 1 |
| Rhee, CS | 1 |
| Kim, CE | 1 |
| Kang, DY | 1 |
| Hyde, TM | 1 |
| Egan, MF | 1 |
| Brown, RJ | 1 |
| Olbrich, HM | 1 |
| Martin, P | 1 |
| Monteleone, P | 1 |
| Piccolo, A | 1 |
| Martino, M | 1 |
| Maj, M | 2 |
| Daniel, DG | 3 |
| Randolph, C | 1 |
| Jaskiw, G | 1 |
| Handel, S | 1 |
| Williams, T | 1 |
| Abi-Dargham, A | 1 |
| Shoaf, S | 1 |
| Egan, M | 1 |
| Elkashef, A | 1 |
| Liboff, S | 1 |
| Jørgensen, HA | 1 |
| Andreassen, OA | 1 |
| Hole, K | 1 |
| Eyles, DW | 1 |
| Stedman, TJ | 1 |
| Pond, SM | 1 |
| Ereshefsky, L | 1 |
| Toney, G | 1 |
| Saklad, SR | 1 |
| Anderson, C | 1 |
| Seidel, D | 1 |
| Chang, WH | 4 |
| Shieh, YS | 1 |
| Liu, HC | 1 |
| Jann, MW | 4 |
| Chien, CP | 1 |
| Kudoh, A | 1 |
| Sakai, T | 1 |
| Ishihara, H | 1 |
| Matsuki, A | 1 |
| Issa, F | 1 |
| Gerhardt, GA | 1 |
| Bartko, JJ | 1 |
| Suddath, RL | 1 |
| Lynch, M | 1 |
| Gamache, PH | 1 |
| Freedman, R | 1 |
| Kirch, DG | 4 |
| Forman, SD | 1 |
| Bissette, G | 1 |
| Yao, J | 2 |
| Nemeroff, CB | 1 |
| Sandyk, R | 3 |
| Kanofsky, JD | 1 |
| Breier, A | 2 |
| Buchanan, RW | 2 |
| Irish, D | 2 |
| Carpenter, WT | 2 |
| Kirkpatrick, B | 2 |
| Davis, OR | 1 |
| Summerfelt, A | 1 |
| Radwan, M | 3 |
| Brandon, J | 2 |
| Baruch, Y | 1 |
| Stawski, M | 1 |
| Tyano, S | 2 |
| Stern, RG | 1 |
| Amin, F | 1 |
| Apter, SH | 1 |
| Hirschowitz, J | 3 |
| Stone, AM | 1 |
| Greenstein, RA | 1 |
| Gamble, G | 2 |
| McLellan, AT | 1 |
| Lin, SK | 2 |
| Juang, DJ | 1 |
| Chen, LC | 1 |
| Yang, CH | 1 |
| Lane, HY | 1 |
| Tatsumi, K | 1 |
| Pickett, CK | 1 |
| Weil, JV | 1 |
| Wei, FC | 1 |
| Lin, HN | 1 |
| Piao-Chien, C | 1 |
| Darby, JK | 1 |
| Pasta, DJ | 1 |
| Dabiri, L | 1 |
| Clark, L | 1 |
| Mosbacher, D | 1 |
| Bartur, P | 2 |
| Yao, JK | 2 |
| Gilbertson, MW | 1 |
| Gurklis, JA | 1 |
| Inosaka, T | 1 |
| Saito, H | 1 |
| Peters, JL | 1 |
| Sato, M | 1 |
| Czobor, P | 3 |
| Volavka, J | 3 |
| Palao, DJ | 1 |
| Araúxo, A | 1 |
| Haro, JM | 1 |
| Brunet, M | 1 |
| Bernardo, M | 1 |
| Miller, DD | 1 |
| Rezai, K | 1 |
| Alliger, R | 1 |
| Andreasen, NC | 1 |
| Hitzemann, R | 2 |
| Piscani, K | 1 |
| Burr, G | 2 |
| Frecska, E | 2 |
| Culliton, D | 1 |
| Mann, M | 1 |
| Curtis, C | 1 |
| Dhopesh, V | 1 |
| Macfadden, A | 1 |
| Maany, I | 1 |
| Weisbard, JJ | 1 |
| Pardo, M | 1 |
| Pollack, S | 1 |
| Bondarenko, ES | 1 |
| Iur'eva, EA | 1 |
| Zykov, VP | 1 |
| Alekseeva, NV | 1 |
| Zimbroff, DL | 1 |
| Kane, JM | 2 |
| Tamminga, CA | 2 |
| Mack, RJ | 1 |
| Wozniak, PJ | 1 |
| Sebree, TB | 1 |
| Wallin, BA | 1 |
| Kashkin, KB | 1 |
| Freeman, HL | 1 |
| Albright, PS | 1 |
| Meszaros, K | 1 |
| Lenzinger, E | 1 |
| Hornik, K | 1 |
| Schönbeck, G | 1 |
| Hatzinger, R | 1 |
| Langer, G | 1 |
| Sieghart, W | 1 |
| Aschauer, HN | 1 |
| Jackson, T | 1 |
| Ditmanson, L | 1 |
| Phibbs, B | 1 |
| Kern, RS | 1 |
| Marshall, BD | 1 |
| Kuehnel, TG | 1 |
| Mintz, J | 1 |
| Hayden, JL | 1 |
| Robertson, MJ | 1 |
| Green, MF | 1 |
| Wirz-Justice, A | 1 |
| Cajochen, C | 1 |
| Nussbaum, P | 1 |
| Bäuml, J | 1 |
| Ferrero, F | 1 |
| Fuger, J | 1 |
| Geretsegger, C | 1 |
| Kasper, S | 1 |
| Kissling, W | 2 |
| Schubert, H | 1 |
| Lee, MS | 1 |
| Kim, YK | 1 |
| Lee, SK | 1 |
| Suh, KY | 1 |
| Moore, DB | 1 |
| Sherr, JD | 1 |
| Love, RC | 1 |
| Hogan, MB | 1 |
| Wilson, NW | 1 |
| Reddy, RD | 1 |
| See, RE | 1 |
| Fido, AA | 1 |
| Maurice, M | 1 |
| Ibrahim, MM | 1 |
| Salama, GM | 1 |
| Rein, W | 2 |
| Coulouvrat, C | 1 |
| Dondey-Nouvel, L | 2 |
| Wassef, AA | 1 |
| Dott, SG | 1 |
| Harris, A | 1 |
| Brown, A | 1 |
| O'Boyle, M | 1 |
| Meyer, WJ | 1 |
| Rose, RM | 1 |
| Colonna, L | 1 |
| Saleem, P | 1 |
| Havaki-Kontaxaki, BJ | 1 |
| Kontaxakis, VP | 1 |
| Christodoulou, GN | 2 |
| Grinshpoon, A | 1 |
| Valevski, A | 1 |
| Moskowitz, M | 1 |
| Stockmeyer, M | 1 |
| Su, JM | 1 |
| Zhang, PY | 2 |
| Al-Sughayir, MA | 1 |
| Davidson, M | 7 |
| Bester, AM | 1 |
| Harvey, BH | 1 |
| Hornik, T | 1 |
| Ishigooka, J | 1 |
| Inada, T | 1 |
| Miura, S | 1 |
| Schutz, G | 1 |
| Smith, RC | 2 |
| Infante, M | 1 |
| Singh, A | 1 |
| Khandat, A | 1 |
| Shen, YC | 1 |
| Varner, RV | 1 |
| Hays, JR | 1 |
| Wagner, AL | 1 |
| Averill, P | 1 |
| Lindenmayer, JP | 1 |
| Citrome, L | 1 |
| Cooper, TB | 3 |
| Chakos, M | 1 |
| Angelopoulos, EK | 1 |
| Markianos, M | 2 |
| Daskalopoulou, EG | 1 |
| Hatzimanolis, J | 2 |
| Tzemos, J | 1 |
| Umbricht, DS | 1 |
| Wirshing, WC | 1 |
| Wirshing, DA | 1 |
| McMeniman, M | 1 |
| Marder, SR | 1 |
| Lykouras, L | 1 |
| Howard, JS | 2 |
| Crayton, J | 1 |
| Dekirmenjian, H | 1 |
| Klass, D | 1 |
| Davis, JM | 1 |
| Elizur, A | 1 |
| Segal, Z | 1 |
| Yeret, A | 1 |
| Aboo-Shach, M | 1 |
| Ben-David, M | 1 |
| Kocher, R | 2 |
| Guerrini, A | 3 |
| Guastalla, A | 3 |
| Rovere, C | 3 |
| Riggi, F | 3 |
| Linn, MW | 1 |
| Caffey, EM | 1 |
| Klett, CJ | 1 |
| Hogarty, GE | 1 |
| Lamb, HR | 1 |
| Zarifian, E | 1 |
| McCreadie, RG | 2 |
| MacDonald, IM | 1 |
| Rompel, H | 1 |
| Segal, H | 1 |
| Lonowski, DJ | 1 |
| Sterling, FE | 1 |
| Kennedy, JC | 1 |
| Walls, P | 1 |
| Gillin, JC | 1 |
| Raft, D | 1 |
| Toomey, T | 1 |
| Gregg, JM | 1 |
| Engelhardt, DM | 1 |
| Rudorfer, L | 1 |
| Rosen, B | 1 |
| Shapiro, AK | 1 |
| Tanghe, A | 1 |
| Declercq, H | 1 |
| Pacquay, M | 1 |
| Brasseur, F | 1 |
| Cutler, NR | 1 |
| Anderson, DJ | 1 |
| Tandon, MK | 1 |
| Itil, TM | 2 |
| Marasa, J | 2 |
| Saletu, B | 2 |
| Davis, S | 1 |
| Mucciardi, AN | 1 |
| Zanoboni, A | 1 |
| Zanoboni-Muciaccia, W | 1 |
| Recchia, M | 1 |
| von Knorring, L | 1 |
| Lindström, E | 1 |
| Barnas, C | 2 |
| Stuppäck, CH | 2 |
| Miller, C | 2 |
| Haring, C | 2 |
| Sperner-Unterweger, B | 2 |
| Fleischhacker, WW | 2 |
| Claus, A | 2 |
| Bollen, J | 2 |
| De Cuyper, H | 2 |
| Eneman, M | 2 |
| Malfroid, M | 2 |
| Heylen, S | 2 |
| Wilms, G | 1 |
| Van Ongeval, C | 1 |
| Baert, AL | 1 |
| van den Bosch, RJ | 1 |
| van Asma, MJ | 1 |
| Rombouts, R | 1 |
| Louwerens, JW | 1 |
| McLaren, S | 1 |
| Cookson, JC | 1 |
| Silverstone, T | 1 |
| Saltz, BL | 1 |
| Glovinsky, D | 1 |
| Koshikawa, H | 1 |
| Suzuki, E | 1 |
| Kanba, S | 1 |
| Nibuya, M | 1 |
| Ishizuki, T | 1 |
| Kohno, H | 1 |
| Kinoshita, N | 1 |
| Shintani, F | 1 |
| Yagi, G | 1 |
| Nakaki, T | 1 |
| Wistedt, B | 2 |
| Koskinen, T | 1 |
| Thelander, S | 1 |
| Nerdrum, T | 1 |
| Pedersen, V | 1 |
| Mølbjerg, C | 1 |
| Eklund, K | 1 |
| Putnam, KM | 1 |
| Powchik, P | 1 |
| McQueeney, R | 1 |
| Davis, KL | 5 |
| Bartlett, EJ | 1 |
| Wolkin, A | 1 |
| Brodie, JD | 1 |
| Laska, EM | 1 |
| Wolf, AP | 1 |
| Sanfilipo, M | 1 |
| Perry, PJ | 1 |
| Alexander, B | 1 |
| Galderisi, S | 1 |
| Mucci, A | 1 |
| Mignone, ML | 1 |
| Kemali, D | 1 |
| Fux, M | 1 |
| Schwartz, A | 1 |
| Knott, P | 1 |
| Kaminsky, R | 1 |
| Cooper, M | 1 |
| DuMont, K | 1 |
| Apter, S | 1 |
| Silver, H | 2 |
| Blacker, M | 2 |
| Weller, MP | 2 |
| Brotman, AW | 1 |
| McCormick, S | 1 |
| Wålinder, J | 1 |
| Holm, AC | 1 |
| Goldberg, TE | 1 |
| Rossi, A | 1 |
| deCataldo, S | 1 |
| Bolino, F | 1 |
| Pacitti, F | 1 |
| Stratta, P | 1 |
| Casacchia, M | 2 |
| Simpson, GM | 1 |
| Yadalam, KG | 1 |
| Levinson, DF | 1 |
| Stephanos, MJ | 1 |
| Lo, ES | 1 |
| Salama, AA | 1 |
| England, RD | 1 |
| Westphal, KP | 1 |
| Grözinger, B | 1 |
| Diekmann, V | 1 |
| Scherb, W | 1 |
| Reess, J | 1 |
| Leibing, U | 1 |
| Kornhuber, HH | 1 |
| Karoum, F | 1 |
| Lawson, WB | 3 |
| Peters, J | 1 |
| van Kammen, WB | 1 |
| Nugent, A | 1 |
| Goetz, KL | 1 |
| Linnoila, M | 1 |
| Thaker, GK | 1 |
| Wagman, AM | 1 |
| Jeste, DV | 1 |
| Hanin, I | 1 |
| Kopp, U | 1 |
| Bagdy, G | 1 |
| Perényi, A | 1 |
| Révai, K | 1 |
| Papp, Z | 1 |
| Fekete, MI | 1 |
| Arató, M | 1 |
| Rosse, RB | 1 |
| Theut, SK | 1 |
| Banay-Schwartz, M | 1 |
| Leighton, M | 1 |
| Scarcella, E | 1 |
| Cohen, CG | 1 |
| Deutsch, SI | 1 |
| Lee, S | 1 |
| Merriam, A | 1 |
| Kim, TS | 1 |
| Liebling, M | 1 |
| Dickson, DW | 1 |
| Moore, GR | 1 |
| Ko, GN | 1 |
| Korpi, ER | 2 |
| Santos, JL | 1 |
| Cabranes, JA | 1 |
| Vazquez, C | 1 |
| Fuentenebro, F | 1 |
| Almoguera, I | 1 |
| Ramos, JA | 1 |
| Lam, YW | 1 |
| Chen, TY | 1 |
| Chen, CT | 1 |
| Hu, WH | 1 |
| Yeh, EK | 1 |
| Mukherjee, S | 1 |
| Roth, SD | 1 |
| Schnur, DB | 1 |
| Igarashi, Y | 1 |
| Toyoshima, R | 1 |
| Noguchi, T | 1 |
| Moroji, T | 1 |
| Marchant, N | 1 |
| Caruso, S | 1 |
| Cuervo, L | 1 |
| Brizuela, A | 1 |
| Lazarus, A | 1 |
| Suárez Richards, M | 1 |
| Smeraldi, E | 1 |
| Bellodi, L | 1 |
| Brancato, V | 1 |
| Komoda, T | 1 |
| Sugishita, M | 1 |
| Yamazaki, J | 1 |
| Miura, M | 1 |
| Sakagishi, Y | 1 |
| Yamauchi, T | 1 |
| Mohs, RC | 3 |
| Losonczy, MF | 3 |
| Silverman, JM | 2 |
| Horvath, TB | 1 |
| Kadysheva, NM | 1 |
| Mokhovikov, AN | 1 |
| Mosketi, KV | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Contreras, SA | 1 |
| Maas, JW | 1 |
| Seleshi, E | 1 |
| Bowden, CL | 1 |
| Bellomo, LE | 1 |
| Rosset, N | 1 |
| Tellarini, L | 1 |
| Forconesi, N | 1 |
| Bamford, CR | 1 |
| Ehmann, TS | 1 |
| Delva, NJ | 1 |
| Beninger, RJ | 1 |
| McKane, JP | 1 |
| Robinson, AD | 1 |
| Wiles, DH | 1 |
| Stirling, GS | 1 |
| Walton, R | 1 |
| Vasavan Nair, NP | 1 |
| Suranyi-Cadotte, B | 1 |
| Achim, A | 1 |
| Lizondo, E | 1 |
| Nayak, R | 1 |
| Song, IS | 1 |
| Small, NA | 1 |
| Johns, CA | 1 |
| Leff, JP | 1 |
| Tress, KH | 1 |
| Bloom, DM | 1 |
| Tourjman, SV | 1 |
| Breitner, JC | 1 |
| Sorokin, JE | 1 |
| McMillan, DE | 1 |
| Fody, EP | 1 |
| Couch, L | 1 |
| Harrison, RH | 1 |
| Newton, JE | 1 |
| Reese, WG | 1 |
| Cabrera, JF | 1 |
| Körner, W | 1 |
| Müller-Oerlinghausen, B | 1 |
| Romani, A | 1 |
| Zerbi, F | 1 |
| Mariotti, G | 1 |
| Callieco, R | 1 |
| Cosi, V | 1 |
| Magliozzi, JR | 1 |
| Braun, T | 1 |
| Zalcman, S | 1 |
| Meco, G | 1 |
| Falaschi, P | 1 |
| Rocco, A | 1 |
| Petrini, P | 1 |
| Rosa, M | 1 |
| Agnoli, A | 1 |
| Yamagami, S | 1 |
| Bütter, HJ | 1 |
| Dutil, C | 1 |
| Franzén, G | 3 |
| Cohen, WJ | 1 |
| Cohen, NH | 1 |
| Serafetinides, EA | 2 |
| Collins, S | 1 |
| Clark, ML | 2 |
| Willis, D | 1 |
| Singh, MM | 1 |
| Smith, JM | 1 |
| Weston, MJ | 1 |
| Bentley, R | 1 |
| Unwin, A | 1 |
| Morris, M | 1 |
| Harper, MA | 1 |
| Gowardman, M | 1 |
| Barrer, B | 1 |
| Brown, RA | 1 |
| Patterson, CD | 1 |
| Keskiner, A | 1 |
| Holden, JM | 1 |
| Vandecasteele, AJ | 1 |
| Vereecken, JL | 1 |
| Hall, WB | 1 |
| Vestre, ND | 1 |
| Schiele, BC | 1 |
| Zimmermann, R | 1 |
| Ban, TA | 2 |
| Villeneuve, C | 1 |
| Ananth, JV | 1 |
| Lehmann, HE | 1 |
| Baro, F | 1 |
| Van Lommel, R | 1 |
| Dom, R | 1 |
| De Mesmaecker, L | 1 |
| Siegel, GJ | 1 |
| Mones, RJ | 1 |
| Saletu, M | 1 |
| Itil, T | 1 |
| DiGiacomo, JN | 1 |
| Fahn, S | 1 |
| Glass, JB | 1 |
| Westlake, RJ | 1 |
| Abuzzahab, FS | 1 |
| Ehlen, KJ | 1 |
| Gurovich, IIa | 1 |
| Fleĭs, EP | 1 |
| Marc, V | 1 |
| Garattini, S | 2 |
| Zaccala, M | 2 |
| Malm, U | 1 |
| Rizzo, M | 1 |
| Yun, BS | 1 |
| Banner, L | 1 |
| Overbey, CB | 1 |
| Brophy, JJ | 1 |
| Song, CK | 1 |
| Chang, HS | 1 |
| Min, KS | 1 |
| Magen, E | 1 |
| Mishal, J | 1 |
| Menachem, S | 1 |
| Valena, V | 1 |
| Young, WG | 1 |
| Slaus, G | 1 |
| Bottenberg, P | 1 |
| Rebandel, P | 1 |
| Rudzki, E | 1 |
| Ørstavik, D | 1 |
| Qvist, V | 1 |
| Stoltze, K | 1 |
| Carmichael, AJ | 1 |
| Gibson, JJ | 1 |
| Walls, AW | 1 |
| Wang, X | 1 |
| Chen, X | 1 |
| Ye, M | 1 |
| Sheftel', VO | 1 |
| Tsam, ZS | 1 |
| Kalinichenko, LT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Six Month, Double Blind, Placebo-controlled Trial of the Efficacy of Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women[NCT01573637] | Phase 3 | 78 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)[NCT02487966] | 132 participants (Actual) | Interventional | 2015-07-31 | Active, not recruiting | |||
| Risperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.[NCT00249119] | Phase 3 | 1,579 participants (Actual) | Interventional | Completed | |||
| Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia[NCT00249132] | Phase 3 | 523 participants (Actual) | Interventional | Completed | |||
| A Double-blind and Randomized Trial of Ginkgo Biloba Extract Added to Risperidone in Treatment-naive First-episode Schizophrenia[NCT01524380] | 124 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures[NCT00409201] | Phase 1 | 30 participants | Interventional | 2006-03-31 | Recruiting | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary endpoint will be the severity of pain measured by changes in PLP from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS pain scale is a simple 10- point scale (0 = ''no pain'', 10 = ''pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -2.84 |
| Active tDCS and Sham Mirror Therapy | -3.35 |
| Sham tDCS and Active Mirror Therapy | -1.78 |
| Sham tDCS and Sham Mirrory Therapy | -2.58 |
The endpoint will be the severity of pain measured by changes in Phantom Limb Sensation from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Sensation scale is a simple 10- point scale (0 = ''no Phantom Limb Sensation'', 10 = ''Phantom Limb Sensation as much as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.86 |
| Active tDCS and Sham Mirror Therapy | -2.55 |
| Sham tDCS and Active Mirror Therapy | -1.35 |
| Sham tDCS and Sham Mirrory Therapy | -2.83 |
The endpoint will be the severity of pain measured by changes in Stump Pain from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Stump Pain scale is a simple 10- point scale (0 = ''no Phantom Limb Stump Pain'', 10 = ''Phantom Limb Stump Pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.31 |
| Active tDCS and Sham Mirror Therapy | -1.9 |
| Sham tDCS and Active Mirror Therapy | -0.91 |
| Sham tDCS and Sham Mirrory Therapy | -0.96 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
10 reviews available for haloperidol and Chronic Disease
| Article | Year |
|---|---|
Brain dysfunction in patients with chronic critical illness.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Chronic Disease; Coma; Comorbid | 2012 |
Neuroleptic concentrations and clinical response.
Topics: Aging; Antipsychotic Agents; Chlorpromazine; Chronic Disease; Drug Interactions; Fluphenazine; Halop | 1984 |
Tics in childhood.
Topics: Child; Chronic Disease; Female; Haloperidol; Humans; Male; Prognosis; Tic Disorders; Tourette Syndro | 1983 |
Haloperidol plasma level monitoring in neuropsychiatric patients.
Topics: Chronic Disease; Drug Resistance; Haloperidol; Humans; Kinetics; Mental Disorders; Nervous System Di | 1982 |
Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double- | 1997 |
Torsade de pointes and low-dose oral haloperidol.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; | 1997 |
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C | 2000 |
Safety profile of amisulpride in short- and long-term use.
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Administration Sc | 2000 |
Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury.
Topics: Adult; Cerebellar Diseases; Cerebellum; Chronic Disease; Dose-Response Relationship, Drug; Fever; Ha | 1989 |
Allergic contact dermatitis to bisphenol-A-glycidyldimethacrylate (BIS-GMA) dental resin associated with sensitivity to epoxy resin.
Topics: Bisphenol A-Glycidyl Methacrylate; Chronic Disease; Cross Reactions; Dermatitis, Allergic Contact; E | 1997 |
106 trials available for haloperidol and Chronic Disease
| Article | Year |
|---|---|
Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans | 2009 |
Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial.
Topics: Adenosine; Adenosine Deaminase; Adult; Chronic Disease; Clozapine; Double-Blind Method; Female; Halo | 2011 |
First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Substitution; F | 2011 |
Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Disease | 2003 |
The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Chronic Disease; Clozapine; Diagnostic and Stat | 2003 |
Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial.
Topics: Adult; Analysis of Variance; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Ethiny | 2003 |
Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol.
Topics: Adult; Antipsychotic Agents; Attention; Chronic Disease; Emotions; Eye Movements; Facial Expression; | 2003 |
The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Double-Blind Method; Factor Analy | 2004 |
Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dibenzothiazepines; Double-Blind Method; Drug Ad | 2004 |
Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Haloperidol; Human | 2006 |
The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.
Topics: Adult; Antioxidants; Antipsychotic Agents; Brief Psychiatric Rating Scale; CD3 Complex; CD4 Lymphocy | 2006 |
Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Diagnostic and Statistical Manual of | 2006 |
A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Chronic Disease; Cognition Disorders; Donepe | 2007 |
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Chronic Disease; Cohort S | 2008 |
[Haloperidol decanoate in replacing combinations of antipsychotic agents in the treatment of chronic schizophrenics].
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combinat | 1984 |
High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Haloperidol; Humans; Male; Mi | 1980 |
A clinical and pharmacodynamic evaluation of sulpiride.
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Middle | 1981 |
Efficacy of risperidone on positive features of schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Haloperidol; Humans; Isoxazoles; | 1994 |
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Haloperidol; Hum | 1995 |
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; | 1995 |
Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study.
Topics: Adult; Chronic Disease; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Female; Foll | 1995 |
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind M | 1993 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.
Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Ma | 1993 |
Coadministration of fluvoxamine increases serum concentrations of haloperidol.
Topics: Adult; Benztropine; Chronic Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 1994 |
Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms.
Topics: Adolescent; Adult; Aged; Blood Proteins; Chronic Disease; Cytosol; Erythrocytes; Female; Haloperidol | 1994 |
Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Resistance; Haloperidol; Humans; Midd | 1994 |
A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses.
Topics: Adult; Biogenic Amines; Chromatography, High Pressure Liquid; Chronic Disease; Dopamine; Double-Blin | 1994 |
Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
Topics: Adult; Chronic Disease; Corticotropin-Releasing Hormone; Double-Blind Method; Haloperidol; Humans; M | 1994 |
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns.
Topics: Adult; Ambulatory Care; Chronic Disease; Clozapine; Double-Blind Method; Female; Follow-Up Studies; | 1993 |
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.
Topics: Adult; Ambulatory Care; Chronic Disease; Clozapine; Double-Blind Method; Female; Haloperidol; Humans | 1994 |
A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Fe | 1996 |
Predicting haloperidol treatment response in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyh | 1996 |
Positive and negative symptoms: is their change related?
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Halop | 1996 |
The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
Topics: Adult; Antipsychotic Agents; Brain; Bromocriptine; Chronic Disease; Dopamine Agonists; Dose-Response | 1997 |
Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Disease Prog | 1997 |
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Chro | 1997 |
Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Canada; Chronic Disease; Cost-Benefit Analysis; Doubl | 1997 |
Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
Topics: Adult; Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Basal Ganglia Diseases; Biperiden; Chroni | 1997 |
Effects of risperidone on polydipsia in chronic schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Chronic Disease; Combined Modality Therapy; Double-Bl | 1997 |
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland.
Topics: Adult; Antipsychotic Agents; Austria; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; | 1997 |
A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.
Topics: Adult; Affect; Antidepressive Agents; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Dr | 1998 |
Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male | 1999 |
Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Comb | 2000 |
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induce | 2000 |
The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Interactions; Drug Therapy, Combination; Female; | 2001 |
Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Length of | 2001 |
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male | 2001 |
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Double-Blind | 2001 |
Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study.
Topics: Adult; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Drug Therapy, Combin | 2001 |
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Double-Blind Method; Dyskinesia, | 2001 |
Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.
Topics: Adult; Antipsychotic Agents; Asian People; Chronic Disease; Double-Blind Method; Female; Haloperidol | 2001 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; | 2001 |
Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale | 2002 |
Day treatment and psychotropic drugs in the aftercare of schizophrenic patients. A Veterans Administration cooperative study.
Topics: Adult; Aftercare; Attitude; Chlorpromazine; Chronic Disease; Cost-Benefit Analysis; Day Care, Medica | 1979 |
High dosage haloperidol in chronic schizophrenia.
Topics: Adult; Alkaline Phosphatase; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Double-Blind | 1977 |
A comparison of the relative efficacy of Serenace and chlorpromazine in the treatment of chronic schizophrenics.
Topics: Adult; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Haloperidol; Huma | 1978 |
Gradual reduction of neuroleptic drugs among chronic schizophrenics. A double-blind controlled study.
Topics: Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Administration | 1978 |
Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Carbidopa; Chlorpromazine; Chronic Disease; Clinical Trials | 1979 |
Haloperidol and thiothixene in the long-term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment.
Topics: Adolescent; Adult; Ambulatory Care; Chronic Disease; Double-Blind Method; Drug Evaluation; Employmen | 1978 |
The behavior therapies: therapeutic breakthrough or latest fad?
Topics: Behavior Therapy; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; History, 20th Cent | 1976 |
Rehabilitation of the chronic patient: experience in the USA.
Topics: Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Mental Disorders; Midd | 1976 |
Higher than usual dosage of haloperidol: a pilot study in 'back ward' schizophrenics.
Topics: Antiparkinson Agents; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Haloperi | 1976 |
Higher than usual dosage of haloperidol: a pilot study in chronic schizophrenics.
Topics: Chronic Disease; Clinical Trials as Topic; Haloperidol; Humans; Psychiatric Status Rating Scales; Sc | 1976 |
Computerized EEG: predictor of outcome in schizophrenia.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Computers; Drug Resistance; Electroencephalography | 1975 |
The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability.
Topics: Antipsychotic Agents; Chronic Disease; Cross-Cultural Comparison; Double-Blind Method; Haloperidol; | 1992 |
Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiepins; Double-Blind Method; Female; Haloperi | 1992 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospit | 1992 |
Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
Topics: Adult; Aged; Antipsychotic Agents; Brain; Cerebral Ventricles; Chronic Disease; Dilatation, Patholog | 1992 |
Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
Topics: Adult; Aged; Chronic Disease; Depression; Double-Blind Method; Female; Fluphenazine; Haloperidol; Hu | 1992 |
Plasma drug level and clinical response.
Topics: Chronic Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychiatric Status Rating Sc | 1992 |
Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric Status R | 1992 |
Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
Topics: Antipsychotic Agents; Benzazepines; Chronic Disease; Haloperidol; Homovanillic Acid; Humans; Male; M | 1991 |
Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Follow-Up S | 1991 |
[Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiepins; Double-Blind Method; Dyskinesia, Drug | 1991 |
Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Dys | 1991 |
A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia.
Topics: Adult; Brain; Chlorprothixene; Chronic Disease; Female; Haloperidol; Humans; Male; Middle Aged; Rece | 1991 |
Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study.
Topics: Adult; Chronic Disease; Cyproheptadine; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 1991 |
Experiences of long-term treatment with remoxipride: efficacy and tolerability.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzamides; Chronic Disease; Double-Blind Method; Dys | 1990 |
Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
Topics: Adult; Affect; Blinking; Cerebral Ventricles; Chronic Disease; Cognition; Concept Formation; Dextroa | 1991 |
Treatment of chronic schizophrenia with cyproheptadine.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Cyproheptadine; Drug Therapy, Combination; Female; | 1989 |
Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
Topics: Adolescent; Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Erythrocytes; Fem | 1989 |
Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 1989 |
Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
Topics: Adult; Biological Availability; Brain; Chronic Disease; Haloperidol; Homovanillic Acid; Humans; Male | 1989 |
[Chronic treatment of schizophrenia with injectable bromperidol decanoate].
Topics: Adult; Brief Psychiatric Rating Scale; Chronic Disease; Clinical Trials as Topic; Female; Haloperido | 1985 |
Urine and plasma levels of dopamine metabolites in response to apomorphine and neuroleptics in schizophrenics.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Apomorphine; Chronic Disease; Clinical Trials as Topic; Diben | 1988 |
[Clinical experience with bromperidol in chronic psychoses].
Topics: Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Inp | 1988 |
Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Flupenthixol; Haloper | 1987 |
Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Fluphenazine; H | 1987 |
A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
Topics: Administration, Oral; Adult; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; | 1986 |
Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures.
Topics: Adult; Brain; Cerebral Ventricles; Chronic Disease; Clinical Trials as Topic; Haloperidol; Humans; M | 1986 |
A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; | 1986 |
A crossover study of clocapramine and haloperidol in chronic schizophrenia.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Basal Ganglia Diseases; Chronic Disease; D | 1985 |
Butaperazine (Repoise).
Topics: Chronic Disease; Clinical Trials as Topic; Haloperidol; Humans; Perphenazine; Phenothiazines; Pipera | 1968 |
Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Analysis of Variance; Bilirubin; Blood Cell Count | 1972 |
Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia.
Topics: Adult; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Clopenthixol; Electroencephalograp | 1972 |
Sleeplessness in acute and chronic schizophrenia--response to haloperidol and anti-parkinsonism agents.
Topics: Acute Disease; Adult; Antiparkinson Agents; Arousal; Benztropine; Chronic Disease; Clinical Trials a | 1973 |
A comparative trial of haloperidol and thioridazine: management of chronic schizophrenia.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Middle Aged; Pl | 1973 |
Pimozide (R6238) in chronic schizophrenia: double blind trial.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Blo | 1973 |
Comparison of phenothiazine and nonphenothiazine neuroleptics according to psychopathology, side effects and computerized EEG.
Topics: Alpha Rhythm; Chronic Disease; Clinical Trials as Topic; Computers; Electroencephalography; Female; | 1974 |
A double-blind clinical evaluation of penfluridol (R 16 341) as a maintenance therapy in schizophrenia.
Topics: Adult; Aged; Antiparkinson Agents; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Drug | 1974 |
A controlled comparison of haloperidol and fluphenazine in chronic treatment-resistant schizophrenics.
Topics: Adult; Aged; Behavior; Chronic Disease; Clinical Trials as Topic; Fluphenazine; Haloperidol; Humans; | 1968 |
Treatment of acute and chronic psychoses with haloperidol: review of clinical results.
Topics: Acute Disease; Chlorpromazine; Chlorprothixene; Chronic Disease; Haloperidol; Humans; Schizophrenia | 1969 |
CI-601, a butyrophenone derivative, in the treatment of chronically withdrawn schizophrenic patients.
Topics: Adult; Butyrophenones; Chronic Disease; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; | 1970 |
Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Evaluation; Electroencephalography; E | 1971 |
A multivariate analysis of the outcome of endodontic treatment.
Topics: Adolescent; Adult; Balsams; Bismuth; Child; Chronic Disease; Drug Combinations; Epoxy Resins; Female | 2004 |
163 other studies available for haloperidol and Chronic Disease
| Article | Year |
|---|---|
Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury.
Topics: Amines; Analgesics; Animals; Antipsychotic Agents; Chronic Disease; Constriction, Pathologic; Cycloh | 2017 |
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2017 |
Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Cardiovascular Diseases; Chronic Disease; Clozapine; Cross-Sectional St | 2018 |
Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastatin [correction of simvastain] in chronic mild stress in mice: a possible link with dopaminergic pathway.
Topics: Animals; Brain-Derived Neurotrophic Factor; Bromocriptine; Chronic Disease; Dopamine; Dopamine Agent | 2014 |
High-Speed imaging reveals opposing effects of chronic stress and antidepressants on neuronal activity propagation through the hippocampal trisynaptic circuit.
Topics: Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Central Ner | 2015 |
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2016 |
The glial phosphorylase of glycogen isoform is reduced in the dorsolateral prefrontal cortex in chronic schizophrenia.
Topics: Aged; Animals; Antipsychotic Agents; Astrocytes; Cells, Cultured; Chronic Disease; Cohort Studies; D | 2016 |
Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs.
Topics: Animals; Antipsychotic Agents; Atrioventricular Block; Chronic Disease; Dogs; Electrocardiography; F | 2017 |
Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem.
Topics: Adult; Age of Onset; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Cohort Studies; Dis | 2008 |
Evaluation of the repeated open-space swim model of depression in the mouse.
Topics: Adaptation, Psychological; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2008 |
[The possibility of high-quality remission in the long chronic course of schizophrenia].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Disease Progression; Drug Therapy, Co | 2008 |
Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Cell Line, Tumor; Chronic Disease; Down-Regulation; Fema | 2009 |
Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism.
Topics: Adult; Alleles; Analysis of Variance; Animals; Antipsychotic Agents; Case-Control Studies; Chronic D | 2010 |
13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients.
Topics: Adult; Animals; Antipsychotic Agents; Breath Tests; Carbon Isotopes; Chronic Disease; Dopamine; Halo | 2012 |
Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients.
Topics: Adult; Animals; Antipsychotic Agents; Blood Platelets; Brain-Derived Neurotrophic Factor; Chronic Di | 2002 |
Quinacrine-induced psychiatric disturbances in a child with common variable immunodeficiency and chronic giardiasis.
Topics: Anti-Anxiety Agents; Antiprotozoal Agents; Antipsychotic Agents; Benzodiazepines; Child; Chronic Dis | 2002 |
Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Animals; Antipsychotic Agents; | 2002 |
Cerebral metabolism and risperidone treatment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Cerebellum; Cerebral Cortex; Chronic Disease; Energy Metabolism; Female | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Cohort Effect; Cohort Studies; Haloperidol; Humans | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Cohort Effect; Dose-Response Relationship, Drug; Drug Adminis | 2003 |
Cerebral metabolic patterns in chronic and recent-onset schizophrenia.
Topics: Acute Disease; Adult; Basal Ganglia; Brain; Brain Mapping; Cerebellum; Cerebral Cortex; Chronic Dise | 2003 |
[Contribution to the study of R-1625 or haloperidol in chronic psychoses or behavior disorders of certain mentally degenerated patients].
Topics: Anesthesia; Chronic Disease; Haloperidol; Hypnotics and Sedatives; Mental Disorders; Psychopharmacol | 1960 |
Fluoxetine augmentation of haloperidol in chronic schizophrenia.
Topics: Adult; Chi-Square Distribution; Chronic Disease; Drug Synergism; Female; Fluoxetine; Haloperidol; Hu | 2003 |
[Influence of long-term quetiapine (Seroquel) and haloperidol therapy on cognitive deficit in patients with paranoid schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Cognition; Dibenzothiazepines; Female; Hal | 2004 |
Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms.
Topics: Aged; Antipsychotic Agents; Chronic Disease; Clozapine; Cognition Disorders; Depressive Disorder, Ma | 2005 |
The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Administration Schedule; Female; Haloperidol; Hum | 2005 |
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Chronic Disease; Double-Blind Meth | 2006 |
Modification of spatial recognition memory and object discrimination after chronic administration of haloperidol, amitriptyline, sodium valproate or olanzapine in normal and anhedonic rats.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Antimanic Agents; Antipsychotic Agents; Be | 2007 |
Clinical efficacy of haloperidol in chronic psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Female; Haloperidol; Humans; Male; Middle A | 1967 |
Human leukocyte antigen A2 and psychopathology in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Haloperidol; HLA Antigens; Humans; Lymphocytes; Recept | 1980 |
[Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
Topics: Adult; Antipsychotic Agents; Bromocriptine; Chlorpromazine; Chronic Disease; Dose-Response Relations | 1980 |
A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Blood Platelets; Chronic Disease; Depression, Chemical; Female; Fluphen | 1981 |
Neuroleptic drugs and erythrocyte catechol-O-methyltransferase in schizophrenia.
Topics: Adult; Antipsychotic Agents; Catechol O-Methyltransferase; Chlorpromazine; Chronic Disease; Erythroc | 1982 |
Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Chronic Disease; Dopamine beta-Hydroxylase; Female; Flu | 1982 |
[Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Female; Haloper | 1984 |
beta-Endorphin and beta-lipotropin plasma levels in chronic schizophrenia, primary affective disorders and secondary affective disorders.
Topics: Adrenocorticotropic Hormone; Adult; beta-Endorphin; beta-Lipotropin; Chronic Disease; Endorphins; Fe | 1981 |
[Influence of nutritional status on intravenous pharmacokinetics of haloperidol in psychotic patients].
Topics: Adult; Body Height; Body Weight; Chronic Disease; Haloperidol; Humans; Injections, Intravenous; Iron | 1984 |
Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation.
Topics: Adult; Bromocriptine; Chronic Disease; Dose-Response Relationship, Drug; Female; Haloperidol; Humans | 1983 |
High-performance liquid chromatography of haloperidol in serum at the concentrations achieved during chronic therapy.
Topics: Bipolar Disorder; Chromatography, High Pressure Liquid; Chronic Disease; Haloperidol; Humans; Kineti | 1984 |
Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies.
Topics: Adult; Baclofen; Chronic Disease; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Halop | 1980 |
High-dose haloperidol increases CSF opioid activity in patients with chronic schizophrenia.
Topics: Adult; Chronic Disease; Endorphins; Female; Haloperidol; Humans; Male; Middle Aged; Schizophrenia | 1983 |
Relapse in patients with shifting RDC diagnoses treated with lithium alone.
Topics: Adult; Bipolar Disorder; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Ha | 1982 |
Prolactin response in tardive dyskinesia.
Topics: Adult; Affective Disorders, Psychotic; Chronic Disease; Dyskinesia, Drug-Induced; Haloperidol; Human | 1982 |
Haloperidol-induced chronic cholestatic liver disease.
Topics: Adolescent; Biopsy; Cholestasis, Intrahepatic; Chronic Disease; Drug Hypersensitivity; Haloperidol; | 1982 |
Haloperidol-induced changes in blink rates correlate with changes in BPRS score.
Topics: Adult; Blinking; Chronic Disease; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scale | 1982 |
Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Drug Administration Schedule; Haloperidol; Humans; Male; Middle Aged; Psychi | 1982 |
Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
Topics: Chronic Disease; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Kinetics; Male; Schi | 1982 |
12-month study of haloperidol decanoate in chronic schizophrenic patients.
Topics: Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; M | 1982 |
Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.
Topics: Basal Ganglia Diseases; Chronic Disease; Female; Haloperidol; Humans; Middle Aged; Prolactin; Schizo | 1980 |
Mobilization of refractory chronic schizophrenics with haloperidol.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperi | 1980 |
Haloperidol blood levels during dosage reduction in chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Sc | 1981 |
Effect of haloperidol administration on serum MHPG-SO4 levels in chronic schizophrenics.
Topics: Adult; Biotransformation; Brain; Chronic Disease; Glycols; Haloperidol; Humans; Male; Methoxyhydroxy | 1981 |
Haloperidol and thiothixene in the long-term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment.
Topics: Adult; Ambulatory Care; Chronic Disease; Employment; Female; Haloperidol; Humans; Male; Middle Aged; | 1980 |
Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin level.
Topics: Chromatography, Gas; Chronic Disease; Dose-Response Relationship, Drug; Haloperidol; Humans; Prolact | 1980 |
Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study.
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Female; Haloperidol; Humans; Injections, | 1980 |
Distractibility in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Attention; Chronic Disease; Cognition Disord | 1995 |
Diurnal variation in tardive dyskinesia.
Topics: Adult; Chronic Disease; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Mal | 1995 |
[Drug treatment of schizophrenic psychoses in puerperium].
Topics: Adult; Antipsychotic Agents; Bromocriptine; Chronic Disease; Clozapine; Dose-Response Relationship, | 1994 |
Seasonal variation in the dexamethasone suppression test: a longitudinal study in chronic schizophrenics and in healthy subjects.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dexamethasone; F | 1994 |
The relationship between motor effects in rats following acute and chronic haloperidol treatment.
Topics: Acute Disease; Animals; Catalepsy; Chronic Disease; Disease Models, Animal; Dyskinesia, Drug-Induced | 1994 |
A loading-dose strategy for converting from oral to depot haloperidol.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Dos | 1993 |
[Emergency caesarean section for a patient with chronic schizophrenia].
Topics: Adult; Anesthesia, Obstetrical; Cesarean Section; Chronic Disease; Emergencies; Female; Fetal Blood; | 1994 |
Vitamin C in the treatment of schizophrenia.
Topics: Adult; Ascorbic Acid; Chronic Disease; Drug Therapy, Combination; Haloperidol; Humans; Male; Schizop | 1993 |
Reduced total complement haemolytic activity in schizophrenic patients.
Topics: Autoimmune Diseases; Bipolar Disorder; Chronic Disease; Complement Activation; Complement C3; Comple | 1993 |
Early response to haloperidol treatment in chronic schizophrenia.
Topics: Adult; Chronic Disease; Cohort Studies; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Psy | 1993 |
Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication.
Topics: Adult; Ambulatory Care; Chronic Disease; Cocaine; Combined Modality Therapy; Comorbidity; Delayed-Ac | 1993 |
Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients.
Topics: Adult; Brain; Chronic Disease; Delayed-Action Preparations; Female; Haloperidol; Homovanillic Acid; | 1993 |
Decreased carotid body hypoxic sensitivity in chronic hypoxia: role of dopamine.
Topics: Anesthesia; Animals; Carotid Body; Carotid Sinus; Cats; Chronic Disease; Domperidone; Dopamine; Dopa | 1995 |
Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Biological Availability; Chronic Disease; Dose-Re | 1995 |
Antinuclear autoantibodies in chronic schizophrenia.
Topics: Adult; Antibodies, Antinuclear; Antipsychotic Agents; Autoantibodies; Autoimmunity; Chronic Disease; | 1995 |
The relationship between plasma haloperidol concentrations and clinical results.
Topics: Chronic Disease; Drug Administration Schedule; Haloperidol; Humans; Psychiatric Status Rating Scales | 1996 |
The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Brain; Brain Mapping; Cerebellum; Cerebral Cortex; Chron | 1997 |
Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cocaine; Comorbidity; Delayed-Action Preparations; Flu | 1997 |
[The laser therapy of children with Tourette's syndrome].
Topics: Adolescent; Antioxidants; Antipsychotic Agents; Child; Chronic Disease; Combined Modality Therapy; F | 1997 |
A schizophrenic patient with an arrhythmic circadian rest-activity cycle.
Topics: Adult; Antipsychotic Agents; Bed Rest; Body Temperature; Catatonia; Chronic Disease; Circadian Rhyth | 1997 |
Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Topics: Antipsychotic Agents; Baltimore; Chronic Disease; Delayed-Action Preparations; Disease-Free Survival | 1998 |
Tourette's syndrome mimicking asthma.
Topics: Adolescent; Antipsychotic Agents; Asthma; Chronic Disease; Cough; Diagnosis, Differential; Haloperid | 1999 |
Human plasma glutathione peroxidase and symptom severity in schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Case-Control Studies; Chronic Disease; Enzyme-Linked Immuno | 1999 |
Prevalence and characteristics of patients with pseudoakathisia.
Topics: Adult; Akathisia, Drug-Induced; Antiparkinson Agents; Antipsychotic Agents; Chlorpromazine; Chronic | 2000 |
Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Brief Psychia | 2000 |
[Pancytopenia].
Topics: Chemical and Drug Induced Liver Injury; Chronic Disease; Diagnosis, Differential; Female; Haloperido | 2000 |
Depot antipsychotics. Patient characteristics and prescribing pattern.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clopenthixol; Delayed-Action Preparations; Drug Utiliz | 2000 |
Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements.
Topics: Animals; Chronic Disease; Corpus Striatum; Cyclic GMP; Dopamine Antagonists; Dyskinesia, Drug-Induce | 2000 |
Outcome comparison of patients receiving oral or depot neuroleptic medication.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chronic Disease; Cohort Studies; Delayed-Action P | 2001 |
Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia.
Topics: Adolescent; Adult; Brain; Chronic Disease; Clomipramine; Dopamine; Haloperidol; Humans; Male; Progno | 2002 |
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clomipramine; Clozapine; Haloperidol; | 2002 |
Somatic profiles in chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Folic Acid Deficiency; Haloperidol; Humans; Hypoglycemia; Hyp | 1976 |
Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Biopharmaceutics; Chronic Disease; Dose-Response Relationship, Drug; Er | 1979 |
[The effect of propranolol, neuroleptics and their combination on serum prolactin levels of schizophrenic patients].
Topics: Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; | 1979 |
[The treatment of chronic low back pain with psychotropic drugs (author's transl)].
Topics: Antidepressive Agents; Back Pain; Central Nervous System; Chronic Disease; Clomipramine; Drug Therap | 1977 |
Neuroendocrine effects of haloperidol therapy in chronic schizophrenia.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adrenocorticotropic Hormone; Adult; Blood Gl | 1975 |
Clinical significance of monitoring plasma levels of psychotropic drugs.
Topics: Adult; Child; Chronic Disease; Clomipramine; Haloperidol; Humans; Mental Disorders; Parasympatholyti | 1979 |
Behavior modification and haloperidol in chronic facial pain.
Topics: Chronic Disease; Face; Female; Haloperidol; Humans; Male; Middle Aged; MMPI; Pain; Pain Management; | 1979 |
A positive response to rapid treatment.
Topics: Adult; Chronic Disease; Haloperidol; Humans; Male; Schizophrenia | 1977 |
The use of psychotropic drugs in the treatment of chronic, severe pains.
Topics: Chronic Disease; Clomipramine; Drug Evaluation; Drug Therapy, Combination; Haloperidol; Humans; Imip | 1976 |
Effect on respiration of diazepam, chloropromazine and haloperidol in patients with chronic airways obstruction.
Topics: Aged; Carbon Dioxide; Chlorpromazine; Chronic Disease; Depression, Chemical; Diazepam; Haloperidol; | 1976 |
Glucose-insulin metabolism in chronic schizophrenia.
Topics: Adult; Chronic Disease; Diabetes Complications; Female; Glucose; Glucose Tolerance Test; Haloperidol | 1975 |
Growth hormone secretion in chronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Female; Growth Hormone; Haloperidol; Humans; Insulin; Male; Midd | 1975 |
Coping style and cognitive dysfunction in schizophrenic patients.
Topics: Activities of Daily Living; Adaptation, Psychological; Adult; Arousal; Attention; Chronic Disease; D | 1992 |
Tardive dyskinesia in the elderly patient.
Topics: Aged; Chlorpromazine; Chronic Disease; Clonazepam; Clozapine; Depressive Disorder; Desipramine; Diph | 1992 |
Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
Topics: Antipsychotic Agents; Chronic Disease; Female; Follow-Up Studies; Haloperidol; Humans; Ireland; Male | 1991 |
Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients.
Topics: Antipsychotic Agents; Chronic Disease; Cohort Studies; Haloperidol; Humans; Male; Risk Factors; Schi | 1991 |
Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia.
Topics: Adult; Basal Ganglia; Blood Glucose; Brain; Brain Mapping; Chronic Disease; Dose-Response Relationsh | 1991 |
Switching haloperidol from oral to im depot formulation.
Topics: Administration, Oral; Biological Availability; Chronic Disease; Dosage Forms; Dose-Response Relation | 1991 |
CEEG mapping in drug-free schizophrenics. Differences from healthy subjects and changes induced by haloperidol treatment.
Topics: Adult; Brain Mapping; Cerebral Cortex; Chronic Disease; Dose-Response Relationship, Drug; Electroenc | 1991 |
A new approach to dose reduction in chronic schizophrenia.
Topics: Adult; Aged; Bromocriptine; Chronic Disease; Dose-Response Relationship, Drug; Growth Hormone; Halop | 1991 |
Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Topics: Administration, Oral; Adult; Chronic Disease; Depression, Chemical; Dopamine; Dopamine Antagonists; | 1991 |
Haloperidol and lithium carbonate treatment did not influence serum immunoglobulin levels in schizophrenic and affective patients.
Topics: Adolescent; Adult; Bipolar Disorder; Chronic Disease; Depressive Disorder; Female; Haloperidol; Huma | 1991 |
A role for high-dose antipsychotics.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration | 1990 |
Increase of spontaneous blink associated with extrapyramidal side effects: a case report.
Topics: Blinking; Chronic Disease; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Middle Aged; Schiz | 1990 |
Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Fluphenazine; Haloperidol; Humans; Injections, In | 1990 |
A case study: schizophrenia and tactile hallucinations, treated with electroconvulsive therapy.
Topics: Adult; Chronic Disease; Combined Modality Therapy; Delusions; Electroconvulsive Therapy; Hallucinati | 1990 |
Slower theta activity over the midfrontal cortex in schizophrenic patients.
Topics: Adult; Biperiden; Chronic Disease; Drug Therapy, Combination; Electroencephalography; Female; Fronta | 1990 |
Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia.
Topics: Adult; Chronic Disease; Circadian Rhythm; Dopamine; Female; Haloperidol; Hospitalization; Humans; Hy | 1987 |
CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
Topics: Adult; Chromatography, High Pressure Liquid; Chronic Disease; Haloperidol; Homovanillic Acid; Humans | 1989 |
Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
Topics: Adult; Antipsychotic Agents; Brain; Chronic Disease; Dyskinesia, Drug-Induced; Electroencephalograph | 1989 |
RBC and plasma choline in neuroleptic-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Brain; Choline; Chronic Disease; Erythrocytes; Female; Haloperidol; Hum | 1989 |
Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antipsychotic Agents; Chronic Disease; Dopamine; Female; Halo | 1985 |
Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Basal Ganglia Diseases; Benztropine; Chronic Disease; Cognitio | 1989 |
Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance.
Topics: Adult; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Dyskinesia, Drug-Induced; Female; | 1989 |
Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drug Tolerance; Female; Haloperidol; Humans; Male; Mid | 1985 |
[Evaluation of the efficacy of haloperidol decanoate in the treatment of chronic psychotic hospital patients].
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Drug Evaluation; Female; Haloperidol; Humans; In | 1985 |
Heatstroke in a chronic schizophrenic patient treated with high-potency neuroleptics.
Topics: Antipsychotic Agents; Benztropine; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, | 1985 |
Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
Topics: Administration, Oral; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Delayed-Action | 1986 |
Effects of neuroleptic treatments on peripheral opioid secretion.
Topics: Adult; Antipsychotic Agents; beta-Endorphin; beta-Lipotropin; Chlorpromazine; Chronic Disease; Diben | 1987 |
Certain neuroleptics reduce bone mineralization in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Bone and Bones; Calcium; Chlorpromazine; Chronic Disease; D | 1987 |
Premorbid sociosexual functioning and long-term outcome in schizophrenia.
Topics: Adult; Aged; Brain; Cerebral Ventricles; Chronic Disease; Haloperidol; Humans; Longitudinal Studies; | 1989 |
[Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia].
Topics: Adolescent; Adult; Aged; alpha-Tocopherol; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; | 1988 |
Gilles de la Tourette's syndrome associated with chronic schizophrenia.
Topics: Adolescent; Chronic Disease; Hallucinations; Haloperidol; Humans; Male; Naltrexone; Schizophrenia, P | 1988 |
Treatment of chronic schizophrenic patients.
Topics: Chronic Disease; Haloperidol; Humans; Schizophrenia | 1988 |
More than mere shots.
Topics: Chronic Disease; Communication; Fluphenazine; Haloperidol; Humans; Mental Disorders; Patient Care Te | 1988 |
The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Female; Haloperidol; Humans; Male; Schizophreni | 1986 |
Verapamil in refractory schizophrenia: a case report.
Topics: Adult; Chronic Disease; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Male; Schiz | 1987 |
Familial schizophrenia and treatment response.
Topics: Adolescent; Adult; Brain; Cerebral Ventricles; Chronic Disease; Haloperidol; Hospitalization; Humans | 1987 |
Drug holidays and serum haloperidol levels in schizophrenic patients.
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Haloperidol; Hospitalization; Humans; Ki | 1986 |
[Successful combined neuroleptic and lithium treatment of a chronic schizophrenic patient with recurrent aggressive behavior].
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Haloperidol; Humans; Lithium; Male; Recurrence; S | 1986 |
Computed tomography and pattern reversal visual evoked potentials in chronic schizophrenic patients.
Topics: Adult; Brain; Chronic Disease; Evoked Potentials, Visual; Haloperidol; Humans; Male; Middle Aged; Sc | 1986 |
Increased urine volume in chronic schizophrenic patients.
Topics: Adult; Benztropine; Chronic Disease; Drinking; Female; Haloperidol; Humans; Hyponatremia; Male; Poly | 1985 |
Elimination half-life and bioavailability of haloperidol in schizophrenic patients.
Topics: Administration, Oral; Adult; Biological Availability; Chronic Disease; Half-Life; Haloperidol; Human | 1985 |
Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Schizop | 1985 |
Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Drug Tolerance; Erectile Dysfunction; Female; Haloperidol; Human | 1985 |
The assessment of a psychosocial treatment with chronic schizophrenic patients using neuropsychopharmacological indices.
Topics: Chronic Disease; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Psychopharmaco | 1985 |
Serum cortisol in chronic schizophrenia. Changes in the response to intravenously administered insulin and ACTH on withdrawal of drugs.
Topics: Adrenocorticotropic Hormone; Aged; Amitriptyline; Blood Glucose; Chronic Disease; Female; Haloperido | 1971 |
Serum cortisol in chronic schizophrenia. A study of the adrenocortical response to intravenously administered insulin and ACTH.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Age Factors; Aged; Amitriptyline; Blood Glucose; Chlorp | 1971 |
Lithium carbonate, haloperidol, and irreversible brain damage.
Topics: Acute Disease; Adult; Bipolar Disorder; Brain; Brain Diseases; Carbonates; Chronic Disease; Consciou | 1974 |
Pimozide treatment of chronic schizophrenics as compared with haloperidol and penfluridol maintenance treatment. A multidisciplinary approach.
Topics: Adult; Attention; Benzimidazoles; Chronic Disease; Haloperidol; Humans; Hydrocarbons, Halogenated; K | 1972 |
Modification of choreiform activity by Haloperidol.
Topics: Administration, Oral; Chorea; Chronic Disease; Electrocardiography; Female; Haloperidol; Humans; Mem | 1971 |
Serum cortisol in chronic schizophrenia. Changes in the diurnal rhythm and psychiatric mental status on withdrawal of drugs.
Topics: Aged; Amitriptyline; Chronic Disease; Circadian Rhythm; Cognition; Female; Haloperidol; Humans; Hydr | 1971 |
A case with Gilles de la Tourette's syndrome: recurrent refractoriness to haloperidol, and unsuccessful treatment with L-dopa.
Topics: Adult; Chlorpromazine; Chronic Disease; Dihydroxyphenylalanine; Drug Synergism; Haloperidol; Humans; | 1971 |
The clinical picture and management of Gilles de la Tourette's syndrome.
Topics: Adolescent; Adult; Child; Chronic Disease; Dose-Response Relationship, Drug; Drug Tolerance; Female; | 1971 |
[A chronic extrapyramidal syndrome as a complication of neuroleptic therapy].
Topics: Aged; Bipolar Disorder; Chlorpromazine; Chronic Disease; Extrapyramidal Tracts; Female; Haloperidol; | 1969 |
Metabolism of exogenous cortisol in humans. Influence of phenobarbital treatment on plasma cortisol disappearance rate.
Topics: Aged; Chronic Disease; Female; Haloperidol; Humans; Hydrocortisone; Male; Microsomes, Liver; Middle | 1970 |
Intramuscular long-acting fluphenazine in the treatment of schizophrenia.
Topics: Administration, Oral; Adult; Aged; Chlorpromazine; Chronic Disease; Fluphenazine; Haloperidol; Human | 1970 |
Haloperidol-desipramine interaction in mice, rats and man.
Topics: Animals; Basal Ganglia Diseases; Benperidol; Butyrophenones; Chronic Disease; Desipramine; Drug Anta | 1970 |
Clinical experience with haldol (haloperidol) in chronic schizophrenics.
Topics: Adult; Chronic Disease; Female; Haloperidol; Humans; Middle Aged; Schizophrenia | 1968 |
Single daily doses of neuroleptic drugs.
Topics: Chlorpromazine; Chlorprothixene; Chronic Disease; Dosage Forms; Fluphenazine; Haloperidol; Humans; M | 1969 |
Endodontic management of supernumerary tooth fused with maxillary first molar by using cone-beam computed tomography.
Topics: Chronic Disease; Composite Resins; Cone-Beam Computed Tomography; Dental Materials; Dental Pulp Cavi | 2010 |
Impact of contact sensitization in chronic spontaneous urticaria.
Topics: Adult; Allergens; Balsams; Chronic Disease; Cobalt; Dermatitis, Allergic Contact; Epoxy Resins; Fema | 2011 |
Dental erosion patterns from intrinsic acid regurgitation and vomiting.
Topics: Adult; Aged; Bicuspid; Bulimia; Case-Control Studies; Chi-Square Distribution; Chronic Disease; Cusp | 2002 |
A survey of endodontic practice amongst Flemish dentists.
Topics: Acute Disease; Analgesics; Anti-Bacterial Agents; Attitude of Health Personnel; Belgium; Bismuth; Ch | 2002 |
Re-patch testing patients with long-term contact dermatitis.
Topics: Chromates; Chronic Disease; Dermatitis, Allergic Contact; Dermatitis, Occupational; Epoxy Resins; Fe | 2002 |
17 cases of epoxy resin dermatitis in Shanghai.
Topics: Acute Disease; China; Chronic Disease; Dermatitis, Allergic Contact; Dermatitis, Occupational; Epoxy | 1992 |
[Hygienic evaluation of epoxide compounds intended for use in the water supply].
Topics: Acute Disease; Animals; Chronic Disease; Epoxy Resins; Female; Filtration; Male; Maximum Allowable C | 1974 |